How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/acute-moraxella-catarrhalis-bronchitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Acute Moraxella catarrhalis bronchitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acute Moraxella catarrhalis bronchitis (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Acute Moraxella catarrhalis bronchitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
ALATROFLOXACIN	ALATROFLOXACIN	Pfizer	alatrofloxacin		1997-01-01
Tomefloxacin	GREPAFLOXACIN	Otsuka	grepafloxacin	Potassium voltage-gated channel subfamily H member 2	1997-01-01
Levaquin	levofloxacin	Generic (originally Daiichi Sankyo/J&J)	Fluoroquinolone Antibacterial [EPC]	CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2	1996-12-20
Biaxin	clarithromycin	Generic (originally Abbott/AbbVie)	Macrolide Antimicrobial [EPC]	Potassium voltage-gated channel subfamily H member 2	1991-10-31
Cefzil	cefprozil	Teva Pharmaceuticals USA	Cephalosporin Antibacterial [EPC]		1991-01-01
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Ofloxacine	Ofloxacine	Assistance Publique - Hôpitaux de Paris		Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1
Ciprofloxacine	Ciprofloxacine	Poitiers University Hospital		DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 7 drugs in Acute Moraxella catarrhalis bronchitis
Assistance Publique - Hôpitaux de Paris · 1 drug in Acute Moraxella catarrhalis bronchitis
Bayer AG · 1 drug in Acute Moraxella catarrhalis bronchitis
Generic (originally Abbott/AbbVie) · 1 drug in Acute Moraxella catarrhalis bronchitis
Generic (originally Daiichi Sankyo/J&J) · 1 drug in Acute Moraxella catarrhalis bronchitis
Otsuka · 1 drug in Acute Moraxella catarrhalis bronchitis
Pfizer · 1 drug in Acute Moraxella catarrhalis bronchitis
Poitiers University Hospital · 1 drug in Acute Moraxella catarrhalis bronchitis
Teva Pharmaceuticals USA · 1 drug in Acute Moraxella catarrhalis bronchitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Acute Moraxella catarrhalis bronchitis:

Cite this brief

Drug Landscape (2026). Acute Moraxella catarrhalis bronchitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/acute-moraxella-catarrhalis-bronchitis. Accessed 2026-06-10.

Acute Moraxella catarrhalis bronchitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing